Therapies

Glucose-lowering medication can influence COVID-19 pathogenesis and could have implications for treating patients with diabetes and COVID-19.

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Blood sugar levels of 70 to 160 mg/dL are considered normal, and anything outside these levels could negatively affect patients.

Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.

The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).

GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.

A1c goals are not a one-size-fits-all; here are some factors you might want to think about to help patients meet their target A1c goals. 

By Sheri Colberg, PhD
In the recent past, we discussed how to know if joint problems (e.g., overuse injuries) are due to being active, aging, or diabetes, but let's focus on aging by itself this time around. Of course, we'd all love to slow down normal aging or even reverse some aspects of it, but is that even possible?

Stroke has been linked to diabetes, but can analysis of fasting glucose provide greater insight into who is most at risk?

DPP-4i may lower the amyloid burden in Alzheimer’s patients and improve cognitive impairment.